News Sentiment

PAR sentiment intelligence

Paradigm Biopharmaceuticals Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 18 relevant articles
Exchange ASX Australia
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.17 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

93/100 classification confidence.

Company focus 18

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-2.9% over one week, +13.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Paradigm Biopharmaceuticals (ASX: PAR) Returns to the Spotlight Ahead of Key Phase 3 Trial Milestone

Market Reaction

Balanced read

69/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 93/100 classification
One-week reaction -2.9% Price reacting lower
Trend fit Trend inactive 13.3% over four weeks
Fair value -52.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 5
Neutral 13
Negative 0

Relevance

Why the article matched

Direct first
Direct company coverage 18
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Kalkine 6
simplywall.st 3
Stocks Down Under 2
TradingView 1
The Globe and Mail 1
Market source 1
Proactive financial news 1
Stockhead 1

Event Lens

What the news is about

Classified themes
Market update 17
Earnings 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-18 of 18